Chen R N, Lakin M M, Montague D K, Ausmundson S
Department of Urology, Cleveland Clinic Foundation, Ohio, USA.
J Urol. 1996 Jan;155(1):138-40.
We attempted to identify risk factors for penile scarring in patients using prostaglandin E1 injection therapy.
Records of 92 patients using prostaglandin E1 therapeutically were reviewed. With statistical methods, patients with (15) and without (77) scarring were compared.
No significant differences between the 2 groups were found regarding duration of followup, injection frequency, prostaglandin E1 dose per injection, total number of injections or total prostaglandin E1 dose. Patients with initial penile scarring did not have a significantly higher incidence of further scarring with prostaglandin E1.
Penile scarring with prostaglandin E1 injection therapy is sporadic and unpredictable. Patients with initial penile scarring do not have a higher incidence of further scarring.
我们试图确定使用前列腺素E1注射疗法的患者阴茎瘢痕形成的危险因素。
回顾了92例接受前列腺素E1治疗的患者的记录。采用统计学方法，对有瘢痕形成（15例）和无瘢痕形成（77例）的患者进行比较。
两组在随访时间、注射频率、每次注射的前列腺素E1剂量、注射总数或前列腺素E1总剂量方面均未发现显著差异。初始阴茎有瘢痕形成的患者使用前列腺素E1后进一步形成瘢痕的发生率并未显著更高。
前列腺素E1注射疗法导致的阴茎瘢痕形成是散发性的且不可预测。初始阴茎有瘢痕形成的患者进一步形成瘢痕的发生率并不更高。
